SCHEMBL16048627

SCHEMBL16048627

O=C1CN(c2ncc(C(=O)O)cn2)CCN1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
OPRM1 P35372 3/20 0.43
OPRL1 P41146 3/20 0.43
AOC3 Q16853 1/20 0.42
HPGDS O60760 1/20 0.40
OGA O60502 1/20 0.40
PRKCH P24723 1/20 0.39
PRKCE Q02156 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 2/20 0.38
PIK3CA P42336 1/20 0.38
P2RY12 Q9H244 1/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
ALDH1A1 P00352 1/20 0.36
SCN9A Q15858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31373403 0.83 AOC3 (0.44) OPRM1OPRL1AOC3HPGDSPRKCH
SCHEMBL25310063 0.80 AOC3 (0.44) OPRM1OPRL1AOC3PRKCHPRKCE
SCHEMBL16053043 0.80 AOC3 (0.44) OPRM1OPRL1AOC3HPGDSPRKCH
SCHEMBL19117494 0.80 AOC3 (0.49) OPRM1OPRL1AOC3OGAPRKCH
SCHEMBL598464 0.79 POLB (0.65) POLBOGAALDH1A1KDM4E
SCHEMBL15415088 0.79 AOC3 (0.42) OPRM1OPRL1AOC3HPGDSPRKCH
SCHEMBL20953955 0.79 KDM4E (0.55) POLBOPRM1OPRL1AOC3PRKCH
SCHEMBL26922564 0.78 AOC3 (0.40) OPRM1OPRL1AOC3HPGDSL3MBTL1
SCHEMBL26924381 0.77 AOC3 (0.42) OPRM1OPRL1AOC3PRKCHPRKCE
SCHEMBL20456745 0.76 AOC3 (0.42) OPRM1OPRL1AOC3PRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PROXIMAGEN LLC (US) 2023-04-13 US disclosed
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN, LLC (US) 2022-11-29 US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-20200262835-A1 COMPOUNDS PROXIMAGEN, LLC (US) 2020-08-20 US disclosed
US-10590125-B2 Compounds PROXIMAGEN, LLC (US) 2020-03-17 US disclosed
US-9428498-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN LIMITED (GB) 2016-08-30 US disclosed
US-9428498-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN LIMITED (GB) 2016-08-30 US disclosed
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2016-02-18 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
WO-2014140592-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LIMITED (GB) 2014-09-18 WO disclosed
US-20140275040-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2014-09-18 US disclosed
US-20140275040-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2014-09-18 US disclosed
US-20140275040-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590125-B2 Compounds ALOX15B, ALOX12, ALOX15 POLB 1500/4885OPRM1 3438/4885OPRL1 2614/4885
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PNPO, XDH, EPX POLB 1538/4885OPRM1 448/4885OPRL1 2465/4885
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH POLB 759/4885OPRM1 1792/4885OPRL1 4029/4885
US-20140275040-A1 NEW COMPOUNDS SSB, ALOX15B, ALOX12 POLB 1376/4885OPRM1 3205/4885OPRL1 2105/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 POLB 1538/4885OPRM1 2256/4885OPRL1 3628/4885
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PNPO, XDH, EPX POLB 1538/4885OPRM1 448/4885OPRL1 2465/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 POLB 1538/4885OPRM1 2256/4885OPRL1 3628/4885
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, AOC3, IL4I1 POLB 1126/4885OPRM1 2503/4885OPRL1 2343/4885
US-20200262835-A1 COMPOUNDS QSOX1, AOX1, EPX POLB 1310/4885OPRM1 288/4885OPRL1 1191/4885
US-20150258101-A1 NEW COMPOUNDS AOX1, QSOX1, MAOB POLB 557/4885OPRM1 408/4885OPRL1 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.